All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the American Association for Cancer Research (AACR) virtual meeting in April 2020, Agata Blasiak, N.1 Institute for Health, NUS, Singapore, SG, presented a poster session about the application of CURATE.AI in multiple myeloma (MM). CURATE.AI is a phenotypic precision medicine (PPM) platform designed to optimize dosing that has been clinically validated and is now being investigated in MM.
Following the AACR meeting, the Multiple Myeloma Hub was pleased to speak to Chng Wee Joo, National University Cancer Institute, Singapore, SG, and Agata Blasiak, about how CURATE.AI may be used to optimize dosing within MM regimens, for individual patients. It was noted that the engineering team are working closely with treating physicians to optimize the platform with the aim of generating effective responses to therapy with minimal toxicity.
What is the potential impact of CURATE.AI on clinical practice in myeloma?
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox